Y0001257
Levetiracetam impurity D
European Pharmacopoeia (EP) Reference Standard
别名:
(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam
等级
pharmaceutical primary standard
API类
levetiracetam
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
N1(CCCC1=O)[C@H](CC)C(=O)N
InChI
1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1
InChI key
HPHUVLMMVZITSG-ZCFIWIBFSA-N
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Iu V Popov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders
[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Gha-hyun Lee et al.
Seizure, 22(3), 185-188 (2013-01-03)
The efficacy and safety of the anti-convulsive drug levetiracetam (LEV) has been well documented but few clinical studies have investigated tolerance to LEV. The aim of this study was to evaluate the loss of the initial efficacy of LEV in
Adel A Mahmoud et al.
Neurosciences (Riyadh, Saudi Arabia), 18(2), 143-146 (2013-04-03)
To compare the effectiveness of 2 novel antiepileptic drugs, topiramate and levetiracetam, as a second line treatment for infantile spasm when oral steroids fail. Forty infants under 2 years with clinically- and EEG-proven infantile spasms that did not respond to
Ellen Mawhinney et al.
Neurology, 80(4), 400-405 (2013-01-11)
Levetiracetam is a broad-spectrum antiepileptic drug (AED) which is currently licensed in the United States and the United Kingdom and Ireland for use as adjunctive treatment of focal-onset seizures and myoclonic seizures or generalized tonic-clonic seizures, occurring as part of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持